1. Home
  2. EDSA vs LGVN Comparison

EDSA vs LGVN Comparison

Compare EDSA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • LGVN
  • Stock Information
  • Founded
  • EDSA 2015
  • LGVN 2014
  • Country
  • EDSA Canada
  • LGVN United States
  • Employees
  • EDSA N/A
  • LGVN N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • LGVN Medicinal Chemicals and Botanical Products
  • Sector
  • EDSA Health Care
  • LGVN Health Care
  • Exchange
  • EDSA Nasdaq
  • LGVN Nasdaq
  • Market Cap
  • EDSA 18.6M
  • LGVN 16.4M
  • IPO Year
  • EDSA N/A
  • LGVN 2021
  • Fundamental
  • Price
  • EDSA $2.66
  • LGVN $0.81
  • Analyst Decision
  • EDSA Strong Buy
  • LGVN Strong Buy
  • Analyst Count
  • EDSA 2
  • LGVN 2
  • Target Price
  • EDSA $13.00
  • LGVN $6.50
  • AVG Volume (30 Days)
  • EDSA 140.8K
  • LGVN 510.4K
  • Earning Date
  • EDSA 12-12-2025
  • LGVN 11-11-2025
  • Dividend Yield
  • EDSA N/A
  • LGVN N/A
  • EPS Growth
  • EDSA N/A
  • LGVN N/A
  • EPS
  • EDSA N/A
  • LGVN N/A
  • Revenue
  • EDSA N/A
  • LGVN $2,073,000.00
  • Revenue This Year
  • EDSA N/A
  • LGVN N/A
  • Revenue Next Year
  • EDSA N/A
  • LGVN N/A
  • P/E Ratio
  • EDSA N/A
  • LGVN N/A
  • Revenue Growth
  • EDSA N/A
  • LGVN 68.67
  • 52 Week Low
  • EDSA $1.55
  • LGVN $0.63
  • 52 Week High
  • EDSA $4.49
  • LGVN $2.48
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 54.92
  • LGVN 47.92
  • Support Level
  • EDSA $2.42
  • LGVN $0.75
  • Resistance Level
  • EDSA $2.95
  • LGVN $0.85
  • Average True Range (ATR)
  • EDSA 0.21
  • LGVN 0.06
  • MACD
  • EDSA 0.01
  • LGVN 0.01
  • Stochastic Oscillator
  • EDSA 49.86
  • LGVN 25.23

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Share on Social Networks: